携带EGFR 19del/C797S/T790M三重突变的肺腺癌对布加替尼和抗EGFR抗体联合治疗有反应。 - Suppr

Lung Adenocarcinoma Harboring EGFR 19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Combination Therapy.

作者信息

Wang Xiaofei, Zhou Ling, Yin Jiani C, Wu Xue, Shao Yang W, Gao Beili

机构信息

Department of Respiratory Diseases and Critical Care Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People's Republic of China.

Medical Department, Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, People's Republic of China.

出版信息

J Thorac Oncol. 2019 May;14(5):e85-e88. doi: 10.1016/j.jtho.2019.01.015. Epub 2019 Jan 31.

DOI:10.1016/j.jtho.2019.01.015

PMID:30711650

Abstract

摘要

相似文献

Lung Adenocarcinoma Harboring EGFR 19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Combination Therapy.携带EGFR 19del/C797S/T790M三重突变的肺腺癌对布加替尼和抗EGFR抗体联合治疗有反应。

J Thorac Oncol. 2019 May;14(5):e85-e88. doi: 10.1016/j.jtho.2019.01.015. Epub 2019 Jan 31.

Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination Therapy.布加替尼与西妥昔单抗联合治疗携带有 EGFR 激活突变、T790M 和 cis-C797S 三重突变的肺腺癌的疗效。

J Thorac Oncol. 2020 Aug;15(8):1369-1375. doi: 10.1016/j.jtho.2020.04.014. Epub 2020 Apr 27.

Possibility of brigatinib-based therapy, or chemotherapy plus anti-angiogenic treatment after resistance of osimertinib harboring EGFR T790M-cis-C797S mutations in lung adenocarcinoma patients.奥希替尼耐药的肺腺癌患者存在 EGFR T790M-cis-C797S 突变时，采用布加替尼为基础的治疗，或化疗联合抗血管生成治疗的可能性。

Cancer Med. 2021 Dec;10(23):8328-8337. doi: 10.1002/cam4.4336. Epub 2021 Oct 6.

Vorinostat combined with brigatinib overcomes acquired resistance in EGFR-C797S-mutated lung cancer.沃利替尼联合布加替尼克服 EGFR-C797S 突变型肺癌的获得性耐药。

Cancer Lett. 2021 Jun 28;508:76-91. doi: 10.1016/j.canlet.2021.03.022. Epub 2021 Mar 26.

Durable Clinical Response of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in trans-C797S to Combination Therapy of First- and Third-Generation EGFR Tyrosine Kinase Inhibitors.携带EGFR 19Del/T790M/反式C797S的肺腺癌对第一代和第三代EGFR酪氨酸激酶抑制剂联合治疗的持久临床反应

J Thorac Oncol. 2019 Aug;14(8):e157-e159. doi: 10.1016/j.jtho.2019.04.020. Epub 2019 May 7.

Early Onset Pulmonary Toxicity With Lorlatinib in a Patient With Previous Pulmonary Toxicity From Brigatinib.一名曾因布加替尼出现肺部毒性的患者使用劳拉替尼后出现早期肺部毒性。

J Thorac Oncol. 2019 Nov;14(11):e247-e248. doi: 10.1016/j.jtho.2019.06.013.

Tyrosine Kinase Inhibition in a Lung Adenocarcinoma Patient With Dual G719S and S768I EGFR Mutations.一名具有G719S和S768I双重表皮生长因子受体（EGFR）突变的肺腺癌患者的酪氨酸激酶抑制作用

J Thorac Oncol. 2018 Aug;13(8):e136-e137. doi: 10.1016/j.jtho.2018.03.021.

A Case of Novel Inversion Mutation of EGFR Exon 19 Leading to Primary Resistance to EGFR TKIs in Lung Adenocarcinoma.一例表皮生长因子受体（EGFR）第19外显子新型倒位突变导致肺腺癌对EGFR酪氨酸激酶抑制剂原发性耐药的病例

J Thorac Oncol. 2018 Jun;13(6):e97-e101. doi: 10.1016/j.jtho.2017.12.014. Epub 2018 Feb 28.

A case of EGFR mutation-positive lung adenocarcinoma in which the T790M allele fraction was increased by repeated EGFR-TKI treatment.1例经反复EGFR-TKI治疗后T790M等位基因分数升高的EGFR突变阳性肺腺癌病例。

Cancer Commun (Lond). 2019 Nov 1;39(1):67. doi: 10.1186/s40880-019-0413-5.

Prevalence of T790M mutation among TKI-therapy resistant Lebanese lung cancer patients based on liquid biopsy analysis: a first report from a major tertiary care center.基于液体活检分析的黎巴嫩 TKI 治疗耐药性肺癌患者 T790M 突变的流行率：来自主要三级护理中心的首次报告。

Mol Biol Rep. 2019 Aug;46(4):3671-3676. doi: 10.1007/s11033-019-04797-5. Epub 2019 May 30.

引用本文的文献

Pathological significance and therapeutic prospects of expression patterns in lung adenocarcinoma.肺腺癌中表达模式的病理意义及治疗前景

Cell Adh Migr. 2025 Dec;19(1):2520632. doi: 10.1080/19336918.2025.2520632. Epub 2025 Jul 4.

Comprehensive liquid biopsy analysis for monitoring NSCLC patients under second-line osimertinib treatment.用于监测接受二线奥希替尼治疗的非小细胞肺癌患者的综合液体活检分析

Front Oncol. 2024 Oct 21;14:1435537. doi: 10.3389/fonc.2024.1435537. eCollection 2024.

A Visual Analysis of the Research Dynamics in Resistance to EGFR Inhibitors for NSCLC.非小细胞肺癌中表皮生长因子受体抑制剂耐药性的研究动态的可视化分析。

Drug Des Devel Ther. 2024 Jun 26;18:2571-2591. doi: 10.2147/DDDT.S465238. eCollection 2024.

A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer.一种大环激酶抑制剂克服了EGFR阳性肺癌中的三重耐药突变。

NPJ Precis Oncol. 2024 Feb 23;8(1):46. doi: 10.1038/s41698-024-00542-9.

Clinical utility of Next Generation Sequencing of plasma cell-free DNA for the molecular profiling of patients with NSCLC at diagnosis and disease progression.血浆游离DNA的下一代测序在非小细胞肺癌患者诊断和疾病进展时分子特征分析中的临床应用

Transl Oncol. 2024 Mar;41:101869. doi: 10.1016/j.tranon.2023.101869. Epub 2024 Jan 29.

Targeting lung cancer with clinically relevant EGFR mutations using anti-EGFR RNA aptamer.使用抗表皮生长因子受体（EGFR）RNA适配体靶向治疗具有临床相关EGFR突变的肺癌。

Mol Ther Nucleic Acids. 2023 Oct 4;34:102046. doi: 10.1016/j.omtn.2023.102046. eCollection 2023 Dec 12.

Survival benefit of anlotinib in T790M-positive non-small-cell lung cancer patients with acquired osimertinib resistance: A multicenter retrospective study and exploratory in vitro study.奥希替尼获得性耐药的 T790M 阳性非小细胞肺癌患者中阿来替尼的生存获益：一项多中心回顾性研究和体外探索性研究。

Cancer Med. 2023 Aug;12(15):15922-15932. doi: 10.1002/cam4.6232. Epub 2023 Jun 30.

The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies.非小细胞肺癌对表皮生长因子受体酪氨酸激酶抑制剂的耐药性：从分子机制到新治疗策略的临床应用

Pharmaceutics. 2023 May 27;15(6):1604. doi: 10.3390/pharmaceutics15061604.

Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance.针对 EGFR 突变型非小细胞肺癌的现行治疗策略：从一线治疗到奥希替尼耐药后。

Jpn J Clin Oncol. 2023 Jun 29;53(7):547-561. doi: 10.1093/jjco/hyad052.

BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non-Small Cell Lung Cancer.BBT-176，一种新型第四代针对非小细胞肺癌奥希替尼耐药 EGFR 突变的酪氨酸激酶抑制剂。

Clin Cancer Res. 2023 Aug 15;29(16):3004-3016. doi: 10.1158/1078-0432.CCR-22-3901.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Lung Adenocarcinoma Harboring EGFR 19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Combination Therapy.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献